Despite mounting evidence that pharma costs have flattened recently, the industry, during recent hearings, took licks from members on both side of the aisle in the divided Congress.
Outsourced Pharma Chief Editor Louis Garguilo continues his coverage of the current state of China pharma manufacturing by interviewing Diana Francis, VP of quality and compliance for BeiGene.
While there are many key aspects of a successful international collaboration across many time zones and great distance, in our experience — a collaboration between organizations based in the U.S. and Japan — there are a few essential elements.
Blockchain technology has shown its value in a number of industries which could be clearly improved through trusted protocol exchange. One, however, that has been slightly undervalued, is regulatory in life sciences.
Without patent protection, efforts to commercialize a repurposed drug have little chance for a reasonable return on investment and are unlikely to attract outside investment.
Intellia Therapeutics CEO, John Leonard, M.D., provides insight into why he entered industry, and his drive to be an entrepreneur.
Dr. Helen Torley, president and CEO of Halozyme Therapeutics, shares a story of how the biopharmaceutical industry makes a difference.
Halozyme Therapeutics’ president and CEO, Dr. Helen Torley, discusses her path to the c-suite, including the formative experience that best prepared her for becoming a CEO.